- » Key resources and services
- » Programs and projects
- » Randomised controlled trial of azithromycin to reduce the morbidity of severe bronchiolitis in young Indigenous children
Randomised controlled trial of azithromycin to reduce the morbidity of severe bronchiolitis in young Indigenous children
This research will investigate bronchiolitis in young Indigenous children and the clinical effectiveness of the drug azithromycin compared with a placebo in treating the illness. In addition to this primary investigation the research will also look at other issues relating to acute lower respiratory tract infections in Indigenous children, specifically:
- determining the effectiveness of treatment on readmissions to hospital within six months
- examining if macrolide* resistant respiratory pathogens (germs) found in swabs taken from the nasal part of the throat influence the severity of the illness
- assessing the short-term impact of azithromycin on macrolide resistant patterns of respiratory germs in the nasal part of the throat
- describing the number of cases of specific respiratory diseases (mycoplasma pneumoniae and chlamydia) present in this population at a certain time and the diversity of the disease using specific sensitive molecular diagnostic techniques.
This research will draw participants from the Royal Darwin Hospital and the Townsville Hospital.
*Macrolide is one in a class of antibiotics that inhibits the growth of bacteria and is often prescribed to treat common bacterial infections.
Australian Indigenous HealthInfoNet abstract
Menzies School of Health Research
McCallum GB, Morris PS, Wilson CC, Versteegh LA, Ward LM, Chatfield MD, Chang AB (2013)
Severity scoring systems: are they internally valid, reliable and predictive of oxygen use in children with acute bronchiolitis?.
Pediatric Pulmonology; 48(8): 797–803